For Immediate Release
Chicago, IL – August 7, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alnylam Pharmaceuticals Inc. (ALNY - Free Report) , GlaxoSmithKline (GSK - Free Report) , Medtronic, Inc. (MDT - Free Report) , Novartis AG (NVS - Free Report) and Biogen Idec Inc. (BIIB - Free Report) .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: https://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Alnylam Earns Milestone Payment
Alnylam Pharmaceuticals Inc. (ALNY - Free Report) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK - Free Report) . The payment was earned due to the progress on the use of their VaxiRNA technology for producing Glaxo’s influenza vaccines. Alnylam has been a leader in the ribo nucleic acid interference (RNAi) technology and its VaxiRNA platform uses the technology to produce more vaccines.
Notably, in November last year, Alnylam and Glaxo entered into a collaboration agreement, which permits Glaxo to use Alnylam’s VaxiRNA technology for producing vaccines. Glaxo, the leading producer of vaccines, is first to utilize Alnylam’s novel VaxiRNA platform for vaccine production.
The collaboration agreement focused primarily on influenza vaccine production in cell culture systems. Apart from the $3.2 million received as milestone payment, Alnylam is also eligible to receive payments on the unit product sales of the vaccines from Glaxo.
We remind investors that the company has alliances with players such as Medtronic, Inc. (MDT - Free Report) , Novartis AG (NVS - Free Report) and Biogen Idec Inc. (BIIB - Free Report) , among others, for its expertise in RNAi therapeutics. Moreover, the company’s core product strategy, Alnylam 5x15, introduced in January 2011, also aims to develop RNAi therapeutic products for the treatment of genetically defined diseases addressing major unmet medical needs. By adopting this strategy, the company aims to have five RNAi therapeutic programs in advanced clinical development by 2015.
We are impressed by Alnylam’s strategy of entering into collaborations with big players in the market. We believe that investor focus will remain on the company’s pipeline going forward. We are also impressed by the company’s 5X15 initiative. We currently have an Outperform recommendation on Alnylam. The stock carries Zacks #1 Rank (‘Strong Buy’ rating) in the short run.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: https://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: https://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=5518.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339